The identification of benzodiazepines (BZD) in biological fluids can be a challenging process. The large number of various BZD in pharmaceutical distribution, with similar core structures, and individual metabolic profiles all contribute to a complicated and time-consuming analysis. The purpose of the current study was to evaluate the performance of four commercially available immunoassay urine screening kits for use in a forensic urine analysis testing program. The four kits included the Roche Benzodiazepine Plus KIMS assay, Microgenics CEDIA | Benzodiazepine assay, Microgenics CEDIA high sensitivity assay with I$-glucuronidase, and Microgenics DRI | reagent ready Benzodiazepine assay. Each kit was evaluated for linearity, precision, accuracy, carryover, reagent specificity, and confirmation rates. BZD reagent specificity was compared by analysis of 55 structurally dissimilar compounds to BZD. Negative responses to all 55 compounds were elicited by all four reagent assays. Cross-reactivity for the assays was demonstrated by detecting 27 structurally similar BZD. In addition, greater than 10,000 randomly collected urine samples were screened at a 200 ng/mL cutoff for each assay. Positive samples were confirmed by gas chromatography-mass spectrometry using a panel of 13 BZD confirmation standards. The Microgenics CEDIA high sensitivity assay demonstrated the highest positive screening rate as well as the highest confirmation rate of the four assays.
Introduction
Benzodiazepines (BZD) are one of the most commonly prescribed drug classes, with over 50 various BZD used as anxiolytics and sedatives for the treatment of anxiety disorders and insomnia (1, 2) . BZD are a safer alternative to barbiturates when used for sedation, hypnosis, anesthesia, anticonvulsant effects, and muscle relaxation (2, 3) . Structurally, BZD are composed of a benzene ring fused to a diazepine ring and a phenyl ring attached at the diazepine C5-position. Substitutions are * Disclaimer: The opinions or assertions herein are those of the authors and do not necessarily reflect the view of the Department of the Navy or the Department of Defense. * Author to whom correspondence should be addressed. E-mail: DeRienz@afip.osd.mil.
possible at five positions on the structure, which allow for the multitude of BZD and accounts for changes in polarity, bioavailability, potency, and the duration of action. For instance, substituting a chloride (clonazepam) or a fluoride (flunitrazepam) at the ortho position of the phenyl ring greatly increases the potency of the compound (4) . Half-lives may range from less than 2 to over 100 h depending on the BZD administered (2, 3, 5) . Most BZD follow similar metabolic pathways (dealkylations, reductions, and hydroxylations followed by conjugation) and also yield similar metabolites, many of which are active and are prescribed compounds (6) (7) (8) (9) (10) (11) . Some common metabolites are oxazepam, temazepam, nordiazepam, and conjugated glucuronides, such as lorazepam glucuronide (9, 10) . In the urinary profile, 30-80% of a BZD dose is found as free and conjugated metabolites (11) .
Forensic analysis of BZD can be difficult for a number of reasons. First, these variations in structure sometimes require more than one confirmation extraction to quantitate the BZD during forensic analysis (12) . Second, many BZD are highly conjugated through metabolism. For example, lorazepam is 75% conjugated, temazepam 73%, and oxazepam 61% (13) (14) (15) . Most immunoassays for initial screening are designed to detect unconjugated BZD and show very little cross-reactivity with conjugated metabolites (7) . For accurate screening of conjugated BZD metabolites, hydrolysis of the samples is required. Enzymatic hydrolysis improves the sensitivity of the kit by increasing the amount of parent BZD available for detection. Third, most BZD have daily doses lower than 60 mg/day, and others, such as alprazolam, have recommended doses of less than I rag/day. The low doses coupled with the relatively short half-life facilitate the need for assays with greater sensitivity (7) (8) (9) (10) 13) .
During immunoassay drug screening, the addition of [~-glucuronidase has shown to be effective in increasing the sensitivity of immunoassay kits for BZD detection by cleaving the glucuronide bond from the metabolites (2, 3, 5, (14) (15) (16) (17) . The Microgenics CEDIA kit used in this study has a high sensitivity option which recommends the addition of [~-glucuronidase to the enzyme acceptor portion of the immunoassay reagent for the cleavage of the conjugated metabolites. This is the first study to present a side-by-side evaluation of these 4 commercially available BZD immunoassay kits to include analysis of a large number of samples, a 13-BZD confirmation panel, and an in-depth cross-reactivity analysis of 27 BZD. Over 10,000 random urine samples were analyzed, and each immunoassay kit was evaluated for precision, accuracy, linearity, carryover, reagent specificity, and confirmation rates. Urinary BZD metabolites are extensively conjugated, so in order to increase detectability, one of the four immunoassay kits was modified to include enzymatic hydrolysis during analysis. This study provides reference data for laboratories seeking to develop or expand their BZD panels and provides information needed in order to choose an immunoassay kit that best fits their particular requirements.
Materials and Methods

Immunoassay
A Roche/Hitachi Modular P automated screening instrument (Indianapolis, IN) was used to test urine samples for BZD. The kits used were Roche Benzodiazepine Plus KIMS assay (Indianapolis, IN), Microgenics CEDIA Benzodiazepine assay, Microgenics CEDIA high sensitivity assay with [3-glucuronidase, and Microgenics DRI reagent ready Benzodiazepine assay (Fremont, CA). The CEDIA high sensitivity assay was prepared by adding 425 ]JL ff-glucuronidase from E. coli K12 (> 200 U/mL, Roche, Indianapolis, IN) to the 65 mL enzyme acceptor reagent for online hydrolysis of conjugated BZD metabolites. Each kit was calibrated on the Modular P analyzer in accordance with manufacturer specifications. As instructed, nordiazepam was used as the calibrator for the Roche kit, nitrazepam was used for both CEDIA kits, and the DRI kit was calibrated with oxazepam. Separate calibrators were spiked at 200 ng/mL with certified standards purchased from Cerilliant (Austin, TX). Instrument settings followed published manufacturers' guidelines. The Modular P instrument was calibrated daily using single point calibration for all assays. Negative (certified negative urine) and positive (125% cutoff concentration) controls were included in the initial calibration. Positive controls were dispersed throughout the sample batch. Negative urine spiked at 0, 100, 150, 200, 250, 300, and 400 ng/mL of each respective calibration drug was used to determine linearity, precision, and accuracy of the assays.
Extraction
StrataTM-XC solid-phase extraction (SPE) columns used in the analysis were purchased from Phenomenex (Torrance, CA). All solvents were high-performance liquid chromatography (HPLC) grade (Fisher Scientific, Fairlawn, NJ). The columns were conditioned successively with 1 mL 2% ammonium hydroxide in ethyl acetate, 3 mL methanol, 3 mL deionized water, and 1 mL 0.1 M pH 4.5 acetate buffer. Urine samples (1 mL) were hydrolyzed by the addition of 2 mL 
St. Louis, MO) followed by incubation at 70~ for 30 rain. Urine samples were applied to the SPE columns and allowed to flow by gravity. The columns were washed with 2 mL deionized water, followed by 2 mL 20% acetonitrile in 0.1 M acetate buffer. The columns were vacuum dried for 10 min. An additional wash using 2 mL hexane was applied, and the columns were dried for 10 min. The samples were eluted using 3 mL 2% ammonium hydroxide in ethyl acetate. Samples were evaporated to dryness using the TurboVap | LV (Zymark, Hopkinton, MA) under nitrogen at 40~ Samples were reconstituted with 40 IlL of (4:1) acetonitrile/MTBSTFA with 1% TBDMCS (Pierce, Rockford, IL), transferred to properly labeled autosampler vials, and capped.
Instrumental analysis
Gas chromatography-mass spectrometry (GC-MS) analysis was performed on an Agilent (Palo Alto, CA) 6890 GC coupled to a 5975 mass selective detector (MSD). The autosampler was controlled by the Agilent ChemStation software (version D.03.00.611). A RTX| capillary column (30 m x 0.25 mm x 0.25 IJm) purchased from Restek (Bellefonte, PA) was used to achieve analytical separation. The helium carrier gas was set at a constant flow of 1.0 mL/min. The injector, containing a 4-mm gooseneck inlet liner with deactivated glass wool, operated in a pulsed splitless mode with a pulse pressure of 35.0 psi. The samples were flash derivatized in the injection port at 295~ The oven temperature was 150~ with a 1.5-rain hold, followed by a 30~ ramp to 265~ held for 1.2 min, and finally a 4~ ramp to 300~ held for 2.72 rain. The total run time was 17 min. The MS acquisition was in selected ion monitoring (SIM) mode acquiring ions for 13 BZD and 5 deuterated internal standards listed in Table I with a linear range of 25 to 1000 ng/mL.
Results and Discussion
Analytical precision, accuracy, and linearity for each immunoassay kit was evaluated through analysis of 10 replicate samples spiked at 0, 100, 150, 200, 250, 300, and 400 ng/mL of the respective calibration drug. Precision of the assay [coefficient of variation (CV)] around each of seven standards was less than 5.73% for all kits. Each kit was evaluated for linearity from 0 to 400 ng/mL. All results are shown in Table II .
Potential carryover was evaluated by spiking negative urines separately with each calibrator and analyzing the sample on the corresponding kit. Each spiked sample was followed by a negative urine sample to identify any carryover, none was observed at 50,000 ng/mL for all kits.
Reagent specificity was evaluated by analyzing 55 nonstructurally related compounds and 27 structurally related compounds. Table III lists all non-structurally related compounds that screened negative at 100,000 ng/mL for all kits. The 27 structurally related compounds included commonly prescribed BZD and metabolites, both unconjugated and conjugated. Three conjugated BZD were analyzed: lorazepam glucuronide, oxazepam glucuronide, and temazepam glucuronide. Table IV lists concentrations evaluated for conjugated metabolites to generate a positive result. The CEDIA high sensitivity kit displayed the most cross-reactivity with the conjugated metabolites while the Roche and CEDIA without glucuronidase had very little cross-reactivity with the conjugates. The DRI kit displayed some response for temazepam glucuronide. In comparison, all four kits produced a positive result for free lorazepam, temazepam, and oxazepam between 100 and 300 ng/mL. Table V shows the cross-reactivity for the remaining 24 structurally similar unconjugated BZD yielding a positive response. Table IV . Conjugated Benzodiazepine Cross-Reactivity CEDIA CEDIAHS* Roche DRI Benzodiazepines (ng/mL) (ng/mL) (ng/mL) (ng/mL)
Lorazepam glucuronide > 10,000 600 > 10,000 > 10,000 Oxazepam glucuronide > 10,000 800 > 10,000 10,000 Temazepam glucuronide > 10,000 750 > 10,000 5000 * High sensitivity, A total of 10,111 randomly collected urine samples were analyzed to evaluate the four BZD screening assays. Each batch was bracketed with a high control at 125% of the calibrator cutoff concentration for each assay. High controls were also dispersed every 150 samples within the batch. Samples that screened positive were confirmed using the previously mentioned confirmation panel. A total of 71 specimens screened positive by at least 1 kit, with 61 specimens confirming positive. Figures 1 and 2 show seven BZD detected with concentration ranges for each as well as combinations of BZD observed. Table VI shows the screen positive rates and confirmation rates for each kit. Screening rates are based on the I00  80  150  25  Estazolam  I00  I00  250  50  Flunitrazepam  150  175  175  750  Flurazepam  50  50  400  150  Lorazepam  150  150  250  250  Midazolam  I00  100  175  25  Oxazepam  150  150  175  200  Prazepam  100  150  300  100  Temazepam  150  150  300  100  Nitrazepam  200  200  200  200  Nordiazepam  125  125  250  25  1-Hydroxyalprazolam 100  120  200  75  1-Hydroxymidazolam  100  125  250  85  1-Hydroxytriazolam  75  115  250  375  7-Aminoflunitrazepam 200  200  250  2000  7-Aminonitrazepam  250  250  250  1500  Lormetazepam  150  150  300  750  Chlordiazepoxide  2500  2500  550  1000  Desalkylflurazepam  125  125 were analyzed to determine if they were present in the 10 samples that screened positive for BZD and confirmed negative. GC-MS and liquid chromatography-electrospray ionization-mass spectroscopy analyses were conducted on these samples. A basic drug extraction was also conducted to identify possible drugs that could have caused the cross-reactivity response. No significant findings or consistent drugs were found in these urine samples to account for the positive screening results.
Conclusions
All four BZD immunoassay kits that were evaluated demonstrated acceptable linearity and precision. There was no observed carryover at 50,000 ng/mL for each kit. Specificity was proven for the non-structurally related compounds analyzed as no positive response was elicited. Analysis of other BZD compounds showed varying results between the kits. Most of the compounds initiated a positive response at reasonable urinary concentrations for all four kits. The Microgenics CEDIA high sensitivity assay demonstrated exceptional response to the conjugated standards analyzed during the study. The other assays were less effective for analysis of the glucuronide conjugate standards. This assay also improved detection of BZD in random urine analysis samples by almost 40% in comparison to the standard CEDIA kit. The increased detection potential for the high sensitivity assay allows for the detection of conjugated metabolites in urine.
